Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Infectious Diseases

Volumn 61, Issue 4, 2015, Pages 572-580

  Mulligan, Kathleen ^a   Glidden, David V ^a   Anderson, Peter L ^b   Liu, Albert ^a,c   McMahan, Vanessa ^d   Gonzales, Pedro ^e   Ramirez Cardich, Maria Esther ^f   Namwongprom, Sirianong ^g   Chodacki, Piotr ^h   De Mendonca, Laura Maria Carvalo ⁱ   Wang, Furong ^a   Lama, Javier R ^f   Chariyalertsak, Suwat ^g,j   Guanira, Juan Vicente ^e   Buchbinder, Susan ^a,c   Bekker, Linda Gail ^h   Schechter, Mauro ⁱ   Veloso, Valdilea G ^k   Grant, Robert M ^a,d   Vargas, Lorena ^l   Sanchez, Jorge ^l   Mai, Chiang ^l   Saokhieo, Pongpun ^l   Murphy, Kerry ^l   Gilmore, Hailey ^l   Holland, Sally ^l   Faber, Elizabeth ^l   Duda, John ^l   Bewerunge, Linda ^l   Batist, Elizabeth ^l   Hoskin, Christine ^l   Brown, Ben ^l   De Janeiro, Rio ^l   Beppu Yoshida, Carina ^l   Da Costa, Marcellus Dias ^l   Assis De Jesus, Sergio Carlos ^l   Grangeiro Da Silva, Jose Roberto ^l   Millan, Roberta ^l   De Siqueira Hoagland, Brenda Regina ^l   Martinez Fernandes, Nilo ^l   Da Silva Freitas, Lucilene ^l   Grinsztejn, Beatriz ^l   Pilotto, Jose ^l   Bushman, Lane ^l   Zheng, Jia Hua ^l   Anthony Guida, Louis ^l   Kline, Brandon ^l   Goicochea, Pedro ^l   Manzo, Jonathan ^l   Hance, Robert ^l   McConnell, Jeff ^l   Defechereux, Patricia ^l   Levy, Vivian ^l   Robles, Malu ^l   Postle, Brian ^l   Burns, David ^l   Rooney, James ^l   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e Investigaciones Medicas en Salud   (United States)

^f ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^g CHIANG MAI UNIVERSITY   (Thailand)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^j Chiang Mai International School   (Thailand)

^k Funda??o Oswaldo Cruz   (Brazil)

^l Rio de Janeiro ^*

more..

Author keywords

bone; DXA; emtricitabine; PrEP; tenofovir

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE; TENOFOVIR;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; CELL LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMALE TO MALE TRANSGENDER; FRACTURE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MULTICENTER STUDY; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; CHEMISTRY; CHEMOPROPHYLAXIS; CYTOPLASM; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHOTON ABSORPTIOMETRY; PLASMA; PROCEDURES;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BONE DENSITY; CHEMOPREVENTION; CYTOPLASM; DOUBLE-BLIND METHOD; EMTRICITABINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PLASMA; TENOFOVIR; YOUNG ADULT;

EID: 84938598621     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ324     Document Type: Article

References (38)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
4. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-60.
5. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
6. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72.
7. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-801.
8. Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of raltegravir combined with boosted darunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One 2014; 9:e106221.
9. Moyle G, Hardy H, Farajallah A, McGrath S, Kaplita S,Ward D. Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy. J Acquir Immune Defic Syndr 2015; 68:40-5.
10. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-50.
11. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
12. Martinez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to oncedaily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51:290-7.
13. Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 2012; 7:e32445.
14. Cotter AG, Vrouenraets SM, Brady JJ, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab 2013; 98:1659-66.
15. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011; 6: e23688.
16. Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of preexposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One 2014; 9:e90111.
17. Lewiecki EM, Gordon CM, Baim S, et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone 2008; 43:1115-21.
18. World Health Organization. Prevention and management of osteoporosis: WHO technical report series 921. Geneva, Switzerland: WHO, 2003.
19. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra25.
20. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997; 16:2349-80.
21. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-61.
22. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8:164-72.
23. Moyle GJ, Stellbrink HJ, Compston J, et al. 96-week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther 2013; 18:905-13.
24. Carr A, Hoy J. Low bone mineral density with tenofovir: does statistically significant mean clinically significant? Clin Infect Dis 2010; 51:973-5.
25. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26:825-31.
26. Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE. Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl) 2011; 3:53-9.
27. Mary-Krause M, Viard JP, Ename-Mkoumazok B, et al. Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. J Clin Densitom 2012; 15:422-33.
28. Mundy LM, Youk AO, McComsey GA, Bowlin SJ. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested casecontrol analysis in a health-insured population. AIDS 2012; 26: 1073-82.
29. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr 2011; 57:205-10.
30. Grijsen ML, Vrouenraets SM, Wit FW, et al. Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis 2013; 207:386-91.
31. Mulligan K, Harris DR, Emmanuel P, et al. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network (ATN) study 021B. Clin Infect Dis 2012; 55:461-8.
32. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395-402.
33. Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24:2827-33.
34. Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 2010; 24:2337-45.
35. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746-54.
36. El-Maouche D, Xu X, Cofrancesco J Jr, Dobs AS, Brown TT. Prevalence of low bone mineral density in a low-income inner-city population. J Bone Miner Res 2011; 26:388-96.
37. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: a clinical practice guideline. Washington, DC: Department of Health and Human Services, 2014:1-67.
38. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-46.